US Bancorp’s Ingevity NGVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $99K | Hold |
1,390
| – | – | ﹤0.01% | 2393 |
|
|
2025
Q4 | $82.3K | Sell |
1,390
-39
| -3% | -$2.12K | ﹤0.01% | 2474 |
|
|
2025
Q3 | $78.9K | Buy |
1,429
+46
| +3% | +$2.39K | ﹤0.01% | 2460 |
|
|
2025
Q2 | $59.6K | Sell |
1,383
-37
| -3% | -$1.43K | ﹤0.01% | 2693 |
|
|
2025
Q1 | $56.2K | Sell |
1,420
-181
| -11% | -$8.01K | ﹤0.01% | 2695 |
|
|
2024
Q4 | $65.2K | Sell |
1,601
-135
| -8% | -$5.62K | ﹤0.01% | 2617 |
|
|
2024
Q3 | $67.7K | Sell |
1,736
-314
| -15% | -$12.5K | ﹤0.01% | 2586 |
|
|
2024
Q2 | $89.6K | Sell |
2,050
-321
| -14% | -$15.5K | ﹤0.01% | 2391 |
|
|
2024
Q1 | $113K | Buy |
2,371
+213
| +10% | +$9.57K | ﹤0.01% | 2299 |
|
|
2023
Q4 | $102K | Sell |
2,158
-81
| -4% | -$3.36K | ﹤0.01% | 2350 |
|
|
2023
Q3 | $107K | Buy |
2,239
+24
| +1% | +$1.31K | ﹤0.01% | 2113 |
|
|
2023
Q2 | $129K | Sell |
2,215
-285
| -11% | -$17.1K | ﹤0.01% | 2071 |
|
|
2023
Q1 | $179K | Sell |
2,500
-289
| -10% | -$22.9K | ﹤0.01% | 1915 |
|
|
2022
Q4 | $196K | Buy |
2,789
+194
| +7% | +$13.7K | ﹤0.01% | 1874 |
|
|
2022
Q3 | $158K | Sell |
2,595
-1,456
| -36% | -$97.7K | ﹤0.01% | 1963 |
|
|
2022
Q2 | $256K | Sell |
4,051
-1,616
| -29% | -$105K | ﹤0.01% | 1769 |
|
|
2022
Q1 | $363K | Sell |
5,667
-191
| -3% | -$12.8K | ﹤0.01% | 1679 |
|
|
2021
Q4 | $420K | Sell |
5,858
-139
| -2% | -$10.6K | ﹤0.01% | 1616 |
|
|
2021
Q3 | $428K | Sell |
5,997
-421
| -7% | -$33.2K | ﹤0.01% | 1605 |
|
|
2021
Q2 | $522K | Sell |
6,418
-1,610
| -20% | -$129K | ﹤0.01% | 1538 |
|
|
2021
Q1 | $605K | Buy |
8,028
+3,341
| +71% | +$243K | ﹤0.01% | 1395 |
|
|
2020
Q4 | $356K | Sell |
4,687
-797
| -15% | -$51.9K | ﹤0.01% | 1614 |
|
|
2020
Q3 | $270K | Sell |
5,484
-1,172
| -18% | -$66.1K | ﹤0.01% | 1631 |
|
|
2020
Q2 | $350K | Buy |
6,656
+505
| +8% | +$24K | ﹤0.01% | 1492 |
|
|
2020
Q1 | $217K | Buy |
6,151
+1,886
| +44% | +$110K | ﹤0.01% | 1627 |
|
|
2019
Q4 | $373K | Sell |
4,265
-330
| -7% | -$28.9K | ﹤0.01% | 1510 |
|
|
2019
Q3 | $390K | Buy |
4,595
+12
| +0.3% | +$1.07K | ﹤0.01% | 1485 |
|
|
2019
Q2 | $482K | Sell |
4,583
-65
| -1% | -$6.53K | ﹤0.01% | 1418 |
|
|
2019
Q1 | $490K | Sell |
4,648
-680
| -13% | -$68.3K | ﹤0.01% | 1394 |
|
|
2018
Q4 | $446K | Sell |
5,328
-172
| -3% | -$15.6K | ﹤0.01% | 1396 |
|
|
2018
Q3 | $561K | Sell |
5,500
-225
| -4% | -$21.7K | ﹤0.01% | 1394 |
|
|
2018
Q2 | $463K | Sell |
5,725
-1,210
| -17% | -$96.2K | ﹤0.01% | 1466 |
|
|
2018
Q1 | $511K | Sell |
6,935
-6
| -0.1% | -$449 | ﹤0.01% | 1429 |
|
|
2017
Q4 | $489K | Buy |
6,941
+1,140
| +20% | +$82.2K | ﹤0.01% | 1448 |
|
|
2017
Q3 | $363K | Sell |
5,801
-983
| -14% | -$58.2K | ﹤0.01% | 1567 |
|
|
2017
Q2 | $390K | Sell |
6,784
-435
| -6% | -$25.6K | ﹤0.01% | 1512 |
|
|
2017
Q1 | $440K | Sell |
7,219
-613
| -8% | -$34.7K | ﹤0.01% | 1446 |
|
|
2016
Q4 | $430K | Sell |
7,832
-2,516
| -24% | -$121K | ﹤0.01% | 1432 |
|
|
2016
Q3 | $476K | Sell |
10,348
-4,226
| -29% | -$178K | ﹤0.01% | 1360 |
|
|
2016
Q2 | $496K | Buy |
+14,574
| New | +$455K | ﹤0.01% | 1319 |
|
Other funds holding NGVT
VPM
VCM
SBH
SCM
US Bancorp's NGVT Position: Q1 2026 in Review
US Bancorp held its Ingevity (NGVT) position steady in Q1 2026 at 1,390 shares worth $99K. The position accounts for ﹤0.01% of the portfolio, ranked #2393.
US Bancorp first reported a position in NGVT in Q2 2016 and has held it in 40 quarters since. The position peaked at $605K in Q1 2021. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.
- US Bancorp held 1,390 shares of Ingevity worth $99K as of Q1 2026.
- US Bancorp left its Ingevity share count unchanged in Q1 2026.
- Ingevity made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2393 holding.
- US Bancorp first reported a position in Ingevity in Q2 2016 and has held it in 40 quarters since.
- US Bancorp's Ingevity position peaked at $605K in Q1 2021.
- 307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.
Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.